X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (91) 91
index medicus (85) 85
male (71) 71
female (66) 66
middle aged (65) 65
adult (63) 63
hematology (61) 61
aged (58) 58
oncology (38) 38
treatment outcome (31) 31
transplantation (29) 29
aged, 80 and over (28) 28
bortezomib (25) 25
adolescent (23) 23
multiple myeloma (21) 21
survival (21) 21
care and treatment (20) 20
disease-free survival (20) 20
stem cells (20) 20
analysis (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
young adult (18) 18
multiple myeloma - drug therapy (17) 17
follow-up studies (16) 16
survival rate (16) 16
therapy (16) 16
cancer (15) 15
chemotherapy (15) 15
dexamethasone (15) 15
prognosis (15) 15
patients (13) 13
recurrence (13) 13
retrospective studies (13) 13
stem-cell transplantation (13) 13
abridged index medicus (12) 12
dexamethasone - administration & dosage (12) 12
essential thrombocythemia (12) 12
medicine, general & internal (12) 12
stem cell transplantation (12) 12
thalidomide - administration & dosage (12) 12
kaplan-meier estimate (11) 11
time factors (11) 11
antineoplastic agents - therapeutic use (10) 10
bone marrow transplantation (10) 10
child (10) 10
mutation (10) 10
transplantation, homologous (10) 10
antineoplastic agents - adverse effects (9) 9
chronic myelogenous leukemia (9) 9
drug resistance, neoplasm (9) 9
expression (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (9) 9
quality of life (9) 9
relapse (9) 9
research (9) 9
risk factors (9) 9
transplantation, autologous (9) 9
antineoplastic agents - administration & dosage (8) 8
article (8) 8
bone marrow (8) 8
clinical trials (8) 8
hematology, oncology and palliative medicine (8) 8
hematopoietic stem cell transplantation (8) 8
hemic and lymphatic diseases (8) 8
hungary (8) 8
janus kinase 2 - genetics (8) 8
leukemia (8) 8
leukemia, myeloid, acute - mortality (8) 8
multiple myeloma - mortality (8) 8
protein kinase inhibitors - therapeutic use (8) 8
remission induction (8) 8
thalidomide - analogs & derivatives (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
diagnosis (7) 7
drug administration schedule (7) 7
genotype (7) 7
hematopoietic stem cells (7) 7
imatinib mesylate (7) 7
myeloproliferative neoplasms (7) 7
risk (7) 7
animals (6) 6
boronic acids - administration & dosage (6) 6
carfilzomib (6) 6
chronic myeloid leukemia (6) 6
clinical medicine (6) 6
dasatinib (6) 6
double-blind method (6) 6
immunology (6) 6
klinisk medicin (6) 6
medical and health sciences (6) 6
medical research (6) 6
medicin och hälsovetenskap (6) 6
medicine & public health (6) 6
multiple myeloma - therapy (6) 6
pathology (6) 6
polycythemia vera (6) 6
pyrazines - administration & dosage (6) 6
remission (6) 6
thalidomide (6) 6
trial (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Hematology, ISSN 0925-5710, 11/2019, Volume 110, Issue 5, pp. 559 - 565
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety... 
Medicine & Public Health | Hematology | Toxicity | Daratumumab | Multiple myeloma | Oncology | Treatment response | Survival | Care and treatment | Refractory materials | Infusion | Renal function | Bortezomib | CD38 antigen | Monoclonal antibodies | Safety
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2016, Volume 374, Issue 17, pp. 1621 - 1634
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Risk groups | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 23, pp. 2492 - 2499
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2017, Volume 177, Issue 3, pp. 404 - 413
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 28, pp. 3549 - 3549
Journal Article